Literature DB >> 15609099

Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Michael G Alexandrakis1, Freda H Passam, Despina S Kyriakou, Constantina Dambaki, George Katrinakis, George Tsirakis, John Konsolas, Efstathios N Stathopoulos.   

Abstract

The myelodysplastic syndromes (MDS) are a group of disorders characterized by dysplastic hemopoiesis and an increased risk of leukemic transformation. The process of angiogenesis has been implicated in the pathogenesis and evolution of MDS. In this study the proliferative activity and extent of angiogenesis was examined in bone marrow samples from 54 patients with MDS in relation to clinicopathologic features. Cellular proliferation and microvascular density (MVD) were examined immunohistochemically, using the monoclonal antibody MIB-1 (Ki-67) and an anti-CD34 monoclonal antibody respectively. Serum concentrations of interleukin-6 (IL-6) were measured by ELISA. The results showed that the MIB-1 Labeling Index (MIB-1 LI), MVD and IL-6 increased significantly with advancing severity of disease. Among the MDS-FAB subtypes, MIB-1 LI, MVD and IL-6 were significantly higher in RAEB-t, RAEB and CMML in comparison to RA and RARS (p < 0.0001 in all cases). Similarly, MIB-1 and MVD were increased in patients with score 3 in comparison to scores 0 and 1 in the IPSS system (p < 0.05). All parameters studied were significantly higher in patients versus controls. We conclude that cellular proliferative activity and angiogenesis are associated with disease progression in MDS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15609099     DOI: 10.1007/s10735-004-2341-0

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  35 in total

Review 1.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

2.  Mechanisms of growth factor expression in acute myeloid leukemia (AML).

Authors:  W Fiedler; E Suciu; C Wittlief; W Ostertag; D K Hossfeld
Journal:  Leukemia       Date:  1990-07       Impact factor: 11.528

3.  Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.

Authors:  M Herold; F Schmalzl; H Zwierzina
Journal:  Leuk Res       Date:  1992 Jun-Jul       Impact factor: 3.156

Review 4.  Angiogenesis in chronic myeloproliferative diseases.

Authors:  F Di Raimondo; G A Palumbo; S Molica; R Giustolisi
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

Review 5.  Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  M Albitar
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

Review 6.  Evaluating the prognosis of patients with myelodysplastic syndromes.

Authors:  C Aul; A Giagounidis; U Germing; A Ganser
Journal:  Ann Hematol       Date:  2002-09-24       Impact factor: 3.673

7.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

8.  Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.

Authors:  W Pellegrini; F Facchetti; D Marocolo; L Salvi; A Capucci; A Tironi; G Rossi
Journal:  Histopathology       Date:  1995-11       Impact factor: 5.087

9.  Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.

Authors:  K Panteli; N Zagorianakou; M Bai; A Katsaraki; N J Agnantis; K Bourantas
Journal:  Eur J Haematol       Date:  2004-06       Impact factor: 2.997

10.  Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

Authors:  A G Leary; K Ikebuchi; Y Hirai; G G Wong; Y C Yang; S C Clark; M Ogawa
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

View more
  7 in total

1.  Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Authors:  Johanna Zannoni; Natacha Mauz; Landry Seyve; Mathieu Meunier; Karin Pernet-Gallay; Julie Brault; Claire Jouzier; David Laurin; Mylène Pezet; Martine Pernollet; Jean-Yves Cahn; Fabrice Cognasse; Benoît Polack; Sophie Park
Journal:  Blood Adv       Date:  2019-06-25

2.  Antiangiogenic therapy in myelodysplastic syndromes: is there a role?

Authors:  Stephen T Oh; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 3.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

4.  Bone marrow cell cycle markers in inherited bone marrow failure syndromes.

Authors:  Mohamad M Al-Rahawan; Blanche P Alter; Barbara J Bryant; M Tarek Elghetany
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

Review 5.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

6.  Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity.

Authors:  Hui Shi; Yingshao Wang; Rong Li; Wen Xing; Feng-Chun Yang; Jie Bai; Yuan Zhou
Journal:  Stem Cells Int       Date:  2018-07-10       Impact factor: 5.443

7.  The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.

Authors:  Sergio Matarraz; Cristina Teodosio; Carlos Fernandez; Manuel Albors; María Jara-Acevedo; Antonio López; María Gonzalez-Gonzalez; María Laura Gutierrez; Juan Flores-Montero; Carlos Cerveró; Marlies Pizarro-Perea; María Paz Garrastazul; Gonzalo Caballero; Oliver Gutierrez; Guy Daniel Mendez; Manuel González-Silva; Paula Laranjeira; Alberto Orfao
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.